 "Natco Pharma gains on USFDA nod for generic Glycopyrrolate tablets")
Natco Pharma was trading higher by 4% to Rs 552, extending its Wednesday’s 6% rally on the BSE, after the company announced that it has received US Food and Drug Administration (FDA) for generic version of Glycopyrrolate tablets.
“We received from our US agent on 22nd June 2016 intimating the approval for generic version of Glycopyrrolate Tablets 1mg and 2mg from US FDA (Reference Listed Drug (RLD) is Robinul Tablets, 1 mg and Robinul Forte Tablets, 2 mg, of Casper Pharma LLC),” Natco Pharma said in a statement.
Glycopyrrolate will be manufactured at the company’s finished dosage facility located at Kothur, near Hyderabad.
Natco Pharma said, the market potential of the product is not significant.
The company believes the product will not have any material or financial impact on its operations, it added.
The stock hit a high of Rs 572 on the BSE in intra-day trade. The trading volumes on the counter jumped more than three-fold with a combined 1.86 million shares changed hands on the BSE and NSE till 01:32 PM.
“We received from our US agent on 22nd June 2016 intimating the approval for generic version of Glycopyrrolate Tablets 1mg and 2mg from US FDA (Reference Listed Drug (RLD) is Robinul Tablets, 1 mg and Robinul Forte Tablets, 2 mg, of Casper Pharma LLC),” Natco Pharma said in a statement.
Glycopyrrolate will be manufactured at the company’s finished dosage facility located at Kothur, near Hyderabad.
Natco Pharma said, the market potential of the product is not significant.
The company believes the product will not have any material or financial impact on its operations, it added.
The stock hit a high of Rs 572 on the BSE in intra-day trade. The trading volumes on the counter jumped more than three-fold with a combined 1.86 million shares changed hands on the BSE and NSE till 01:32 PM.